



Divi's Laboratories Limited

May 23, 2026

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on May 23, 2026

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our letter dated May 14, 2026, we would like to inform that the Board of Directors of the Company at its meeting held on May 23, 2026 has approved inter alia, the following items of business:

Financial Results

Approved the Statement of Audited financial results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of Audited Standalone Financial Results for the quarter and year ended March 31, 2026 and Auditors' Report thereon.
2. Statement of Audited Consolidated Financial Results for the quarter and year ended March 31, 2026 and Auditors' Report thereon.
3. Declaration regarding Audit Reports with unmodified opinion.
4. Press release on financial results.

Dividend, Annual General Meeting and Record date

Recommended a final dividend of ₹30/- (i.e. 1,500%) per equity share of face value ₹2/- each for the financial year 2025-26, subject to approval of the members at the ensuing 36th Annual General Meeting (AGM). The dividend shall be paid within specified timelines from the conclusion of the AGM.

The 36th AGM of the Members of the Company will be held on August 10, 2026. The record date for the purpose of the payment of dividend is July 24, 2026.

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854

E-mail : mail@divislabs.com, Website : www.divislabs.com



Divi's Laboratories Limited

The Board meeting commenced at 10.15 Hrs and concluded at 11.50 Hrs.

This is for your information and records.

Thanking you,

Yours faithfully,

For Divi's Laboratories Limited

M. Satish Choudhury

Company Secretary & Compliance Officer


DIVI'S LABORATORIES LIMITED
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ in Crores)

S. No.	Particulars	Quarter ended			Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited) **	(Unaudited)	(Audited) **	(Audited)	(Audited)
1	Income:					
	Revenue from operations	2793	2578	2536	10388	9198
	Other Income	154	87	87	506	352
	Total Income	2947	2665	2623	10894	9550
2	Expenses					
	a) Cost of materials consumed	1173	1191	910	4260	3760
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods work-in-progress and stock-in-trade	(70)	(246)	59	(244)	(83)
	d) Employee benefits expense	370	356	341	1400	1210
	e) Depreciation and amortisation expense	120	116	107	461	401
	f) Finance costs	6	6	-*	23	1
	g) Other expenses	377	370	345	1484	1332
	Total expenses	1976	1793	1762	7384	6621
3	Profit before exceptional items and tax (1-2)	971	872	861	3510	2929
4	Exceptional items Impact of new Labour Codes (Refer note 4)	-	74	-	74	-
5	Profit before Tax (3-4)	971	798	861	3436	2929
6	Tax expense					
	a) Current tax	250	208	225	869	793
	b) Deferred tax	(35)	(8)	(31)	(40)	(73)
	Total tax expense	215	200	194	829	720
7	Profit for the Period/Year (5-6)	756	598	667	2607	2209
8	Other comprehensive income:					
	Items that will not be reclassified to Profit or Loss:					
	(i) Gain/(loss) on Remeasurement of post-employment benefit obligations	(8)	17	(1)	8	(3)
	(ii) Income tax relating to the above	2	(4)	-*	(2)	1
	Total Other comprehensive income/(loss) (i+ii)	(6)	13	(1)	6	(2)
9	Total comprehensive Income for the period/year (7+8)	750	611	666	2613	2207
10	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	53	53	53	53	53
11	Other Equity excluding revaluation reserve				16658	14842
12	Earnings per Share of Rs. 2/- each (not annualized)#					
	a) Basic (Rs.)	28.44	22.56	25.12	98.19	83.20
	b) Diluted (Rs.)	28.44	22.56	25.12	98.19	83.20

* Amount is below the rounding off norm adopted by the Company.

#Earnings per share calculated on actual amount of profit after tax in rupees.



Kai Di



DIVI'S LABORATORIES LIMITED

STANDALONE AUDITED STATEMENT OF ASSETS AND LIABILITIES

(₹ in Crores)

	Particulars	As At	
		31.03.2026	31.03.2025
		Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	6514	5436
	Capital work-in-progress	2113	1022
	Intangible assets	6	4
	Financial assets		
	a) Investments	76	72
	b) Other financial assets	67	62
	Income tax assets (net)	1	1
	Other non-current assets	143	248
	Sub-total: Non-current assets	8920	6845
2	Current assets		
	Inventories	3711	3033
	Financial assets		
	a) Trade receivables	3228	2855
	b) Cash and cash equivalents	85	396
	c) Bank balances other than (b) above	3286	3300
	d) Other financial assets	8	16
	Income tax assets (net)	14	12
	Other current assets	702	367
	Sub-total: Current assets	11034	9979
	TOTAL ASSETS	19954	16824
B	EQUITY AND LIABILITIES		
1	Equity:		
	Equity Share Capital	53	53
	Other Equity	16658	14842
	Sub-total: Total equity	16711	14895
2	Liabilities:		
	Non-current liabilities		
	Financial liabilities		
	(a) Other financial liabilities	456	-
	Provisions	81	-
	Deferred tax liabilities (net)	469	509
	Other non-current liabilities	218	-
	Sub-total: Non-current liabilities	1224	509
3	Current Liabilities		
	Financial liabilities		
	a) Borrowings	-	2
	b) Trade payables:		
	Total outstanding dues of micro and small enterprises	62	37
	Total outstanding dues other than above	1128	843
	c) Other financial liabilities	460	408
	Provisions	60	54
	Current tax liabilities (net)	11	-
	Other current liabilities	298	76
	Sub-total: Current liabilities	2019	1420
	Total Liabilities	3243	1929
	TOTAL EQUITY AND LIABILITIES	19954	16824



Kan Di



DIVI'S LABORATORIES LIMITED
STANDALONE AUDITED STATEMENT OF CASH FLOWS

(₹ in Crores)

Particulars	For the year ended	
	31.03.2026 (Audited)	31.03.2025 (Audited)
A. Cash flow from operating activities		
Profit before tax	3436	2929
Adjustments for:		
Depreciation and amortisation expense	461	401
Unrealised foreign exchange (gain)/loss	(106)	6
Interest income from financial assets at amortised cost	(284)	(295)
Change in fair value of investment in optionally convertible debentures	(4)	(1)
Gain on redemption of investments	-	(4)
Provision for doubtful debts/ (written back) including bad debts written off/ (recovered)	1	1
Interest expense	23	1
Loss on disposal / discard of property, plant and equipment and intangible assets	-*	4
Amortisation of government grants	-*	-*
	3527	3042
Change in operating assets and liabilities		
(Increase) /Decrease in trade receivables	(261)	(592)
(Increase) /Decrease in inventories	(678)	(48)
(Increase) /Decrease in other financial assets	3	(15)
(Increase) /Decrease in other assets	(334)	(49)
Increase /(Decrease) in employee benefit obligation	95	7
Increase /(Decrease) in trade payables	303	82
Increase/ (Decrease) in other financial liabilities	478	-
Increase /(Decrease) in other liabilities	440	41
Cash generated from operations	3573	2468
Income tax paid including withholding tax and net of refunds	(862)	(818)
Net cash inflow from operating activities	2711	1650
B. Cash flows from investing activities		
Payments for property, plant and equipment	(2519)	(1437)
Proceeds from sale of property, plant and equipment	3	-*
Proceeds from redemption of optionally convertible debentures	-	22
Interest received	284	295
Proceeds from withdrawal of deposits	6156	3541
Investment in deposits	(6142)	(3224)
Net cash outflow from investing activities	(2218)	(803)
C. Cash flows from financing activities		
Interest paid	(5)	(1)
Dividend paid to company's shareholders	(797)	(796)
Net cash outflow from financing activities	(802)	(797)



Handwritten signature in blue ink.



DIVI'S LABORATORIES LIMITED

STANDALONE AUDITED STATEMENT OF CASH FLOWS (contd.)

(₹ In Crores)

Particulars	31.03.2026 (Audited)	31.03.2025 (Audited)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(309)	50
Cash and cash equivalents at the beginning of the financial year	394	344
Cash and cash equivalents at end of the year	85	394
Reconciliation of cash and cash equivalents at the end of the year		
Cash and cash equivalents as per Balance sheet	85	396
Overdraft facilities from bank	-	(2)
Balance as per Statement of cash flows	85	394


* Amount is below the rounding off norm adopted by the Company.

NOTES:

- The above Statement of standalone audited financial results for the quarter and year ended March 31, 2026, Standalone audited statement of assets and liabilities and Standalone audited statement of cash flows as at and for the year ended March 31, 2026 ('Standalone statements') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Standalone statements have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 23, 2026. The statutory auditors have audited the standalone statements and issued an unmodified report thereon.
- The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108.
- The Company does not have any discontinued operations and the Profit for the year represents the Profits from continuing operations only.
- On November 21, 2025, the Government of India notified the four labour codes viz., the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') consolidating twenty-nine existing labour laws. The Ministry of Labour and Employment notified central rules and issued FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the impact based on the best available information and recognised the incremental impact of employee benefits expense of Rs.74 crores. The said incremental impact primarily arises due to change in the definition of wages and the same has been accounted in accordance with the applicable accounting standards. Considering its non-recurring nature and amount involved, such incremental impact is presented under "Exceptional items" in the Standalone statements. The Company continues to monitor the developments pertaining to implementation of Labour Codes and will provide the appropriate impact in accordance with applicable accounting standards, if any.
- **Financial results for the quarter ended March 31, 2026 and corresponding quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years, which were subject to limited review.
- The Board of Directors of the Company has recommended a dividend of ₹ 30/- per share of face value ₹ 2/- each i.e. 1500 % for the financial year 2025-26, subject to approval of members at the ensuing annual general meeting.
- Forex gain included in Other Income for the respective periods is as given below

(₹ in Crores)

	Quarter ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	(Audited)**	(Unaudited)	(Audited)**	(Audited)	(Audited)
Forex gain	89	18	11	210	48



Place: Hyderabad
Date: May 23, 2026

For Divi's Laboratories Limited


Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer



Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report

To the Board of Directors of Divi's Laboratories Limited

Report on the Audit of Standalone Financial Results

Opinion

1. We have audited the accompanying standalone annual financial results of Divi's Laboratories Limited (the "Company") for the year ended March 31, 2026 and the standalone statement of assets and liabilities as on that date and the standalone statement of cash flows for the year ended on that date, attached herewith, which are included in the accompanying 'Statement of standalone audited financial results for the quarter and year ended March 31, 2026', 'Standalone audited statement of assets and liabilities' and 'Standalone audited statement of cash flows' (together referred to as the "standalone financial results") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") which has been initialled by us only for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us, the standalone financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2026 and the standalone statement of assets and liabilities and the standalone statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the standalone financial results
Page 2 of 3

Board of Directors' Responsibilities for the Standalone Financial Results

4. These standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the standalone statement of assets and liabilities and the standalone statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the standalone financial results by the Directors of the Company, as aforesaid.
5. In preparing the standalone financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

7. Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the standalone financial results
Page 3 of 3

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The standalone financial results include the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



N.K. Varadarajan
Partner
Membership Number: 90196
UDIN: 26090196SLQTQN8953

Place : Hyderabad
Date : May 23, 2026

DIVI'S LABORATORIES LIMITED


**STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026**

(₹ in Crores)

S. No	Particulars	Quarter ended			Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited)**	(Unaudited)	(Audited)**	(Audited)	(Audited)
1	Income:					
	Revenue from operations	2831	2604	2585	10560	9360
	Other Income	155	88	86	507	352
	Total Income	2986	2692	2671	11067	9712
2	Expenses					
	a) Cost of materials consumed	1214	1217	931	4378	3821
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(95)	(272)	50	(285)	(96)
	d) Employee benefits expense	381	367	350	1442	1243
	e) Depreciation and amortisation expense	120	118	107	463	402
	f) Finance costs	6	6	1	23	2
	g) Other expenses	397	402	368	1584	1424
	Total expenses	2023	1838	1807	7605	6796
3	Profit before exceptional Items and tax (1-2)	963	854	864	3462	2916
4	Exceptional items					
	Impact of new Labour Codes (Refer note 5)	-	74	-	74	-
5	Profit before Tax (3-4)	963	780	864	3388	2916
6	Tax expense					
	a) Current tax	249	208	228	868	799
	b) Deferred tax	(37)	(11)	(26)	(48)	(74)
	Total tax expense	212	197	202	820	725
7	Profit for the Period/Year (5-6)	751	583	662	2568	2191
8	Profit for the period/ year attributable to:					
	Shareholders of the Company	751	583	662	2568	2191
	Non-Controlling Interest	-	-	-	-	-
9	Other comprehensive income:					
a)	Items that will not be reclassified to Profit or Loss:					
	i) Gain/(loss) on Remeasurement of post-employment benefit obligations	(8)	17	(1)	8	(3)
	ii) Income tax relating to the above	2	(4)	-	(2)	1
b)	Items that will be reclassified to Profit or Loss:					
	i) Gain/(loss) on exchange differences in translating the financial statements of foreign operations	7	4	1	20	6
	ii) Income tax relating to the above	(2)	(1)	-	(5)	(1)
	Total Other comprehensive Income/(loss) (a+b)	(1)	16	-	21	3
10	Total other comprehensive income for the year/period attributable to:					
	Shareholders of the Company	(1)	16	-	21	3
	Non-Controlling Interest	-	-	-	-	-
11	Total comprehensive Income for the period/year (7+9)	750	599	662	2589	2194
12	Total comprehensive income for the period/ year attributable to:					
	Shareholders of the Company	750	599	662	2589	2194
	Non-Controlling Interest	-	-	-	-	-
13	Paid-up Equity Share Capital (Face Value: Rs 2/- per share)	53	53	53	53	53
14	Other equity excluding revaluation reserve				16708	14916
15	Earnings per Share of Rs 2/- each (not annualized)#					
	a) Basic (Rs)	28.31	21.98	24.93	96.75	82.53
	b) Diluted (Rs)	28.31	21.98	24.93	96.75	82.53

Amount is below the rounding off norm adopted by the group.

#Earnings per share calculated on actual amount of profit after tax in rupees.



Kan Di




DIVI'S LABORATORIES LIMITED

CONSOLIDATED AUDITED STATEMENT OF ASSETS AND LIABILITIES

(₹ in Crores)

	Particulars	As At	
		31.03.2026	31.03.2025
		Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	6515	5437
	Right of use assets	7	1
	Capital work-in-progress	2113	1022
	Intangible assets	6	4
	Financial assets		
	a) Investments	69	65
	b) Other financial assets	67	62
	Income tax assets (net)	3	1
	Deferred tax asset	14	11
	Other non-current assets	143	248
	Sub-total: Non-current assets	8937	6851
2	Current assets		
	Inventories	3954	3236
	Financial assets		
	a) Trade receivables	2984	2731
	b) Cash and cash equivalents	128	415
	c) Bank balances other than (b) above	3286	3300
	d) Other financial assets	8	16
	Income tax assets (net)	15	13
	Other current assets	721	370
	Sub-total: Current assets	11096	10081
	TOTAL ASSETS	20033	16932
B	EQUITY AND LIABILITIES		
1	Equity:		
	Equity Share Capital	53	53
	Other Equity	16708	14916
	Sub-total: Total equity	16761	14969
2	Liabilities:		
	Non-current liabilities		
	Financial liabilities		
	a) Other financial liabilities	456	-
	b) Lease liabilities	5	2
	Provisions	81	-
	Deferred tax liabilities (net)	469	509
	Other non-current liabilities	218	-
	Sub-total: Non-current liabilities	1229	511
3	Current Liabilities		
	Financial liabilities		
	a) Borrowings	-	2
	b) Lease liabilities	2	-*
	c) Trade payables:		
	Total outstanding dues of micro and small enterprises	62	37
	Total outstanding dues other than above	1149	873
	d) Other financial liabilities	460	409
	Provisions	60	54
	Current tax liabilities (net)	12	-
	Other current liabilities	298	77
	Sub-total: Current liabilities	2043	1452
	Total Liabilities	3272	1963
	TOTAL EQUITY AND LIABILITIES	20033	16932



Kai Di



DIVI'S LABORATORIES LIMITED
CONSOLIDATED AUDITED STATEMENT OF CASH FLOWS

(₹ in Crores)

Particulars	For the year ended	
	31.03.2026 (Audited)	31.03.2025 (Audited)
A. Cash flow from operating activities		
Profit before tax	3388	2916
Adjustments for:		
Depreciation and amortisation expense	463	402
Unrealised foreign exchange loss/ (gain)	(86)	9
Interest income from financial assets at amortised cost	(284)	(295)
Change in fair value of investments in optionally convertible debentures	(4)	(1)
Gain on redemption of investments	-	(4)
Provision for doubtful debts/ (written back) including bad debts written off/ (recovered)	1	(2)
Interest expense	23	2
Loss on disposal / discard of property, plant and equipment and intangible assets	-*	4
Amortisation of government grants	-*	-*
	3501	3031
Change in operating assets and liabilities		
(Increase) /Decrease in trade receivables	(141)	(582)
(Increase) /Decrease in inventories	(718)	(52)
(Increase) /Decrease in other financial assets	2	(15)
(Increase) /Decrease in other assets	(350)	(50)
Increase /(Decrease) in employee benefit obligation	95	7
Increase /(Decrease) in trade payables	294	95
Increase/ (Decrease) in other financial liabilities	478	-
Increase /(Decrease) in other liabilities	439	43
Cash generated from operations	3600	2477
Income tax paid including withholding tax and net of refunds	(862)	(824)
Net cash inflow from operating activities	2738	1653
B. Cash flows from investing activities		
Payments for property, plant and equipment	(2520)	(1438)
Proceeds from sale of property, plant and equipment	3	-*
Proceeds from redemption of optionally convertible debentures	-	22
Interest received	284	295
Proceeds from withdrawal of deposits	6156	3541
Investment in deposits	(6142)	(3224)
Net cash outflow from investing activities	(2219)	(804)
C. Cash flows from financing activities		
Interest paid	(5)	(2)
Principal elements of lease liabilities	(2)	(1)
Dividends paid to company's shareholders	(797)	(796)
Net cash outflow from financing activities	(804)	(799)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(285)	50
Cash and cash equivalents at the beginning of the financial year	413	363
Cash and cash equivalents at end of the year	128	413



Kai Di



DIVI'S LABORATORIES LIMITED
CONSOLIDATED AUDITED STATEMENT OF CASH FLOWS (contd.)

(₹ in Crores)

Particulars	31.03.2026 (Audited)	31.03.2025 (Audited)
Reconciliation of cash and cash equivalents at the end of the year		
Cash and cash equivalents as per Balance sheet	128	415
Overdraft facilities from bank	-	(2)
Balance as per Statement of cash flows	128	413

* Amount is below the rounding off norm adopted by the group.

NOTES:

- The above Statement of consolidated audited financial results for the quarter and year ended March 31, 2026, Consolidated audited statement of assets and liabilities and Consolidated audited statement of cash flows as at and for the year ended March 31, 2026 ('Consolidated statements') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('IndAS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Consolidated statements have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 23, 2026. The statutory auditors have audited the consolidated statements and issued an unmodified report thereon.
- The consolidated financial results include the audited financial results of the wholly owned subsidiaries viz., Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.
- The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108.
- The Group does not have any discontinued operations and the Profit for the year represents the Profits from continuing operations only.
- On November 21, 2025, the Government of India notified the four labour codes viz., the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') consolidating twenty-nine existing labour laws. The Ministry of Labour and Employment notified central rules and issued FAQs to enable assessment of the financial impact due to changes in regulations. The Parent Company has assessed the impact based on the best available information and recognised the incremental impact of employee benefits expense of Rs.74 crores. The said incremental impact primarily arises due to change in the definition of wages and the same has been accounted in accordance with the applicable accounting standards. Considering its non-recurring nature and amount involved, such incremental impact is presented under "Exceptional items" in the Consolidated statements. The Parent Company continues to monitor the developments pertaining to implementation of Labour Codes and will provide the appropriate impact in accordance with applicable accounting standards, if any.
- **Financial results for the quarter ended March 31, 2026 and corresponding quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years, which were subject to limited review.
- The Board of Directors of the company has recommended a dividend of ₹30/- per share of face value ₹ 2/- each i.e.1500% for the financial year 2025-26, subject to approval of members at the ensuing annual general meeting.
- Forex gain included in Other Income for the respective periods is as given below.

(₹ in Crores)

	Quarter ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	(Audited)**	(Unaudited)	(Audited)**	(Audited)	(Audited)
Forex gain	90	19	10	211	48



For Divi's Laboratories Limited

Kiran S Divi
Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer



Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report

To the Board of Directors of Divi's Laboratories Limited

Report on the Audit of Consolidated Financial Results

Opinion

1. We have audited the accompanying consolidated annual financial results of Divi's Laboratories Limited (the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), (refer note 2 to the consolidated annual financial results) for the year ended March 31, 2026 and the consolidated statement of assets and liabilities as on that date and the consolidated statement of cash flows for the year ended on that date, attached herewith, which are included in the accompanying 'Statement of consolidated audited financial results for the quarter and year ended March 31, 2026', 'Consolidated audited statement of assets and liabilities' and 'Consolidated audited statement of cash flows' (the "consolidated financial results") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") which has been initialled by us only for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial results:
 - (i) include the annual financial results of the following entities: Divi's Laboratories Limited, Divis Laboratories (USA) Inc., and Divi's Laboratories Europe AG;
 - (ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (iii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2026 and the consolidated statement of assets and liabilities and the consolidated statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Consolidated Financial Results' section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the consolidated financial results
Page 2 of 3

Board of Directors' Responsibilities for the Consolidated Financial Results

4. These consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group and the consolidated statement of assets and liabilities and the consolidated statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.
5. In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the respective companies or to cease operations, or has no realistic alternative but to do so.
6. The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

7. Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the consolidated financial results
Page 3 of 3

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the financial results/ financial information of the entities within the Group to express an opinion on the consolidated financial results.
9. We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
11. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matter

12. The consolidated financial results include the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



N.K. Varadarajan
Partner
Membership Number: 90196
UDIN: 26090196SHUAUN1055

Place: Hyderabad
Date: May 23, 2026



Divi's Laboratories Limited

May 23, 2026

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir / Madam,

Sub: Declaration regarding Audit Reports with unmodified opinion

Ref: Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015

With reference to the above, we hereby declare that the Statutory Auditors of the Company, M/s. Price Waterhouse Chartered Accountants LLP, Chartered Accountants, Hyderabad (Firm registration number: 012754N/N500016) have issued Audit Reports with Unmodified Opinion on the Statements of Standalone and Consolidated Audited Financial Results for the financial year ended March 31, 2026.

This is for your information and records.

Thanking you,
Yours faithfully,
For Divi's Laboratories Limited


Venkatesa Perumallu Pašumarthy
Chief Financial Officer





DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com

PRESS RELEASE DATED 23rd MAY 2026

Divi's Laboratories earns a Consolidated Total Income of ₹ 11067 Crores for Financial Year 2025-26

Consolidated Financial Results

For the quarter ended 31st March 2026

Divi's Laboratories Ltd has earned a consolidated total income of ₹ 2986 crores for the quarter ended 31st March 2026 as against a consolidated total income of ₹ 2671 crores for the corresponding quarter of the previous year. Profit before tax (PBT) for the quarter amounted to ₹ 963 crores as against a PBT of ₹ 864 crores for the corresponding quarter of the previous year. Profit after tax (PAT) for the quarter amounted to ₹ 751 crores as against a PAT of ₹ 662 crores for the corresponding quarter of the previous year. For the current quarter, we have a forex gain of ₹ 90 crores as against a forex gain of ₹ 10 crores for the corresponding quarter of the previous year.

For the financial year 2025-26

For the financial year 2025-26, the Company earned a consolidated total income of ₹ 11067 crores as against a consolidated total income of ₹ 9712 crores for the previous financial year. Profit before tax (PBT) for the current financial year amounted to ₹ 3388 crores (after the impact of labour codes of ₹ 74 Crores) as against ₹ 2916 crores for the previous financial year. Profit After Tax (PAT) for the current financial year is ₹ 2568 crores as against ₹ 2191 crores for previous financial year. For the current financial year, we have a forex gain of ₹211 crores against a gain of ₹ 48 crores for the previous financial year.

Standalone Financial Results

On a standalone basis, the Company's earnings are as given below:

Particulars	For the Quarter ended		For the Year ended	
	31-03-2026	31-03-2025	31-03-2026	31-03-2025
Total Income	2947	2623	10894	9550
PBT before exceptional item	971	861	3510	2929
Exceptional Item*	-	-	74	-
PBT	971	861	3436	2929
Tax Expense	215	194	829	720
PAT	756	667	2607	2209

*Employee Benefit Expenses – Statutory impact of labour codes





DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032,
Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com

Forex gain for the period, on standalone basis, is as given below:

₹ in crores

Particulars	For the Quarter ended		For the Year ended	
	31-03-2026	31-03-2025	31-03-2026	31-03-2025
Forex gain	89	11	210	48

Dividend:

The Board of Directors at their meeting held on 23rd May 2026, has recommended a Dividend of ₹ 30/- per equity share of ₹ 2/- each i.e, 1500% for the financial year 2025-26 subject to the approval of the Members at the ensuing Annual General Meeting of the Company.

Kai Di

